ARS Pharmaceuticals

ARS PHARMACEUTICALS INC

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Jim Cramer- AI Is Bigger Than Rate Cuts

Analyst Color

Long Ideas

News

Markets

Media

Trading Ideas

BMRN

GTLB

OKLO

SPRY

Jim Cramer recommends Union Pacific but is &#34;getting tired of the orphan drug model.&#34; Here&#39;s what the &#34;Mad Money&#34; host said.

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs

Jabil Inc.

Intraday Update

Movers

CAPR

CLEU

CVNA

FIVE

GAMB

IMCR

TITN

Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday

Boy,Using,Nasal,Spray,Bottle.-,Allergy,Concept

Biotech

Health Care

General

FDA approves ARS Pharma&#39;s Neffy 1 mg, the first nasal epinephrine spray for children with severe allergies, offering a needle-free alternative to autoinjectors.

FDA Approves ARS Pharmaceuticals&#39; Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment

ARS Pharmaceuticals Inc

Press Releases

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Earnings

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

Biohaven

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Denali Therapeutics

89bio

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Vericel

Veracyte

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Scotiabank

Raymond James

Leerink Partners

Cantor Fitzgerald

Wedbush

Comments

ARS Pharmaceuticals

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell